ENGLEWOOD, Colo., July 23 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the opening of its new headquarters, manufacturing and research facility:
Ampio Pharmaceuticals,
373 Inverness Parkway
Englewood, CO 80112
Direct: (720) 437-6500
Michael Macaluso, Ampio's CEO, noted "This advanced, labor efficient, pharmaceutical drug manufacturing facility will be fully operational this summer, right on schedule, to produce the first batches of Ampion(TM) necessary to accommodate the company's BLA application to treat osteoarthritis-of-the- knee (OAK). This factory is designed to manufacture and package 10 million doses per year of Ampion(TM) as an injectable drug for the treatment of osteoarthritis as well as for additional formulations of Ampion(TM) to treat other clinical indications. This factory will be fully compliant with regulatory requirements for both the USA and international medical manufacturing. Also located in this facility are State-of-the-art molecular biology and analytical research laboratories."
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.
|
